Popular Articles

Also In Global Health News: Text Messages To Fight Polio; TB At Pakistani Relief Camps; ARV Supply In Uganda
UNICEF Using SMS Text Messages To Fight Polio In Zambia
generic viagra online
Tapentadol Tablets For Moderate To Scute Pain In Over 18s Now Available For Use In The United States
German pain expert company GrÃønenthal GmbH announces that the new centrally acting analgesic tapentadol is now available in the United States. The drug is indicated for the relief of moderate to severe acute pain in patients 18 years of age and older. Approval was given by the US Food and Drug Administration (FDA) in November 2008 for tapentadol (NUCYNTATM) tablets. With the cooperation of GrÃønenthal and its marketing partner Ortho-McNeil-Janssen Pharmaceuticals, Inc., the medication can now be prescribed by physicians and other appropriate health care professionals in the United States.
News of the day
HSE Warns Businesses Not To Be Misled Over New Law Poster, UK
The Health and Safety Executive (HSE) is warning businesses across Britain not to be duped into buying unnecessary and overpriced copies of its health and safety law poster.
Mental Health

Broad Therapy For Muscular Dystrophy

A group led by Dr. Paul T. Martin of The Ohio State University College of Medicine has demonstrated that the glycosyltransferase Galgt2 can lessen symptoms in multiple models of muscular dystrophy. Their report can be found in the July 2009 issue of the American Journal of Pathology. Muscular dystrophy is a group of inherited muscular disorders that are characterized by progressive skeletal muscle weakness, defects in muscle proteins, and the death of muscle cells and tissue. Recent studies have shown that a number of genes can prevent muscle damage, even though they do not fix the genetic defect that causes the disease. However, these surrogate gene therapies have had limited applicability across different forms of muscular dystrophy. High expression of the protein Galgt2, which alters the expression and properties of other proteins expressed in skeletal muscle, lessens the symptoms of muscular dystrophy in models with decreased expression of either dystrophin or laminin. Xu et al examined the effects of Galgt2 overexpression in a mouse model of limb girdle muscular dystrophy 2D. Galgt2 overexpression resulted in lower levels of muscle damage, and galgt2 gene therapy protected muscle fibers from injury. Increasing Galgt2 expression may therefore have therapeutic benefits in a broad range of muscular dystrophies. Dr. Martin and colleagues "have developed [a] gene therapy approach to overexpress the Galgt2 cDNA. ò€¦Future work will entail developing methods to allow systemic delivery of such gene therapy vectors using the human Galgt2 cDNA driven by muscle- or muscle/heart-specific promoters. ò€¦ [They also plan to] identif[y] drugs that would increase [Galgt2] expression in muscle ò€¦ to stimulate the therapeutic effects of Galgt2 over-expression." Xu R, DeVries S, Camboni M, Martin PT: Overexpression of Galgt2 reduces dystrophic pathology in the skeletal muscles of alpha sarcoglycan-deficient mice. Am J Pathol 2009, 174: 2645-2657 Angela Colmone American Journal of Pathology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):